Brief: Kazia Therapeutics Provides Update On Paxalisib Regulatory Pathway Following Type C Meeting With FDA
31/12/2024 13:54
Dec 31 (Reuters) - Kazia Therapeutics Ltd KZIA.O :
* KAZIA THERAPEUTICS PROVIDES UPDATE ON PAXALISIB REGULATORY
PATHWAY FOLLOWING TYPE C MEETING WITH FDA
* KAZIA THERAPEUTICS LTD - FDA SAYS OS DATA NOT APPROPRIATE
FOR
ACCELERATED APPROVAL
* KAZIA THERAPEUTICS LTD - FDA COMMENTS OS DATA SUPPORTIVE
FOR
PIVOTAL REGISTRATIONAL STUDY
* KAZIA THERAPEUTICS LTD - ALIGNS WITH FDA ON PHASE 3 STUDY
DESIGN
Source text: ID:nPn5mLr4Da
Further company coverage: KZIA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering